The increase of megakaryocytes and platelets that characterizes essential thrombocythemia (ET) appears to be secondary to a deregulation of megakaryocytopoiesis. The carboxy-terminal fragment of osteogenic growth peptide (OGP10-14) promotes bone formation and hemopoiesis, while it inhibits megakaryocytopoiesis. In this paper we show that treatment with synthetic OGP10-14 (sOGP10-14) induces a significant reduction of mid and large colony-forming unit-megakaryocytes (CFU-Mk) in ET patients as well as in controls, and is associated with a significant inhibition of thrombopoietin (TPO)-primed MO-7e megakaryoblastic cells proliferation. These actions appear to be related to sOGP10-14 modulation of TGF-beta(1) synthesis and/or secretion, although a direct effect on TGF-beta receptor expression cannot be excluded.
|Autori:||FAZZI R; GALIMBERTI S; PACINI S; TESTI R; AZZARA' A; ORCIUOLO E; TROMBI L; METELLI M.R; PETRINI M|
|Titolo:||Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide; III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia|
|Anno del prodotto:||2004|
|Appare nelle tipologie:||1.1 Articolo in rivista|